ARDX, Roland Rick Perry

And we Have Another Triple! Ardelyx (ARDX) Touches $5.00, up 333%.

LIVE QUOTE Longer Term Chart Ardelyx Enters the Danger Zone* With Tenapanor.

We’re Bearish, but we’re up 243% in Provention Bio (PRVB) Today.

And up 416%, from Adding it to 2022 Watch List! Great way to wake up after a night of...
Unicycive

Unicycive (UNCY) Shoots and Scores, up 40% Today!

We're up 126% Since December, and That Ain't Bad. Note: This isn't the end, it's just the...

Booya. We’re up 143% With Ardelyx (ARDX) in Three Months – and That Ain’t...

Ardelyx Adds 16% to $3.82 as Wedbush Upgrades After Q4 Earnings. Ardelyx ( NASDAQ: ARDX ) gained 35%...
Silo Pharma, Psychedelic Stock Review, Roland Rick Perry

SILO Pharma (SILO) Gains 53%

For Now, Volatility Remains and the Traders, Seem to be Having the Most Fun. Silo Pharma Gains 53%...

He Shoots And He Scores. Ardelyx (ARDX) Gains 78%. Happy New Year!

Ah yes, and Gains Come to the Patient, as the FDA Moves the Ardelyx Ball Further Along.

Provention Bio (PRVB) Gains 26% Last Week.

We're up 106% From Adding to the 2022 Watch List Last July. And up 26% a Week After Urging Holders to Calm...

FDA Approval for Provention Bio (PRVB).

Re-cork the Champagne! We were contemplating (dreaming) about an opening price over $12, and then a drift up...

Adding Ardelyx (ARDX) $1.57 to Watch List.

FDA Advisory Committee Says Go Forth Young Man! While we hadn't previously owned Ardelyx, nor are they a...

Provention Biosciences (PRVB) Enters the Danger Zone.

Chart Looks Beautiful - But Nervous is why, we use soft and dry. LIVE QUOTE We'll...

Latest article

Hundreds of Stocks Have Fallen Below $1. They’re Still Listed on Nasdaq. (WSJ)

Investor-protection advocates say many belong to risky small companies that should be on the OTC market. With 557 names...

Selling Under Cash. LQR House (LQR) Addresses Nasdaq Delisting.

If You're a Sophisticated Speculator, and we do Mean Sophisticated, Study LQR House (LQR) or 'the Liquor House' Story.

LQR House (LQR). And the Numbers are In!

A Situation Which Can't be Ignored! That's not to say run out and buy it, but this current valuation...